Jak tyrosine kinases contain a tyrosine kinase (JH1) domain adjacent to a catalytically inactive pseudokinase domain (JH2). The JH2 domain has been implicated in regulation of Jak activity, but its function remains poorly understood. Here, we found that the JH2 domain negatively regulates the activity of Jak2 and Jak3. Deletion of JH2 resulted in increased tyrosine phosphorylation of the Jak2 and Jak3 JH2 deletion mutants as well as of coexpressed Stat5. In cytokine receptor signalling, the deletion of the Jak2 and Jak3 JH2 domains resulted in IFN-γ and IL-2 -independent Stat activation, respectively. However, cytokine stimulations did not further induce the JH2 deletion mutant mediated Stat activation. The deletion of the Jak2 JH2 domain also abolished IFN-γ -inducible kinase activation, although it did not affect the reciprocal Jak1-Jak2 interaction in 293T cells. Chimeric constructs, where the JH2 domains were swapped between Jak2 and Jak3, retained low basal activity and cytokine inducible signalling, indicating functional conservation between the two JH2 domains.
Introduction
Janus (Jak) 1 machrophage colony stimulating factor (GM-CSF) (1) . Lack of Jak2 causes embryonic lethality in mice due to absence of definitive erythropoiesis, and these cells also fail to respond to interferon-γ (IFN-γ), IL-3, IL-5 and GM-CSF (4, 5) . On the other hand, Jak3 has been found as the only signalling molecule so far to associate with the common γ chain of IL-2, IL-4, IL-7, IL-9 and IL-15 receptors (6) . Lack of functional Jak3 results in Severe
Combined Immunodeficiency (SCID) with varying defects on T-and B-cells both in human and in mice (7) (8) (9) (10) .
The Jak kinases are characterized by the presence of seven regions of sequence similarity found between Jak kinases and designated as Jak homology (JH) domains (11) . JH1 is a catalytically active tyrosine kinase domain located in the C-terminus of Jak kinases and next to it is JH2, also called the pseudokinase or kinase-like domain. The JH2 domain has conserved sequence motifs found in protein kinases, but these motifs are subtly modified and consequently, the JH2 domain is catalytically inactive. Interestingly, the modifications are conserved between the JH2 domains of different Jak kinases, suggesting that the JH2 domain has an important function in Jak kinases. Recently, sequence based predictions have indicated 4 in cell surface expression of cytokine receptors (19, 20) . The FERM domain of Jak3 was recently also found to positively regulate kinase activity, while no such function has been assigned to this domain in Jak2 or Tyk2 (21) (22) (23) (24) . The function of the SH2 domain in Jak kinases is currently unknown.
In cytokine receptors, Jak activation is achieved through ligand-induced aggregation of receptor chains bringing the associated Jak kinases in close contact. Ligand binding most likely induces a conformational change in the receptor cytoplasmic domains allowing formation of a multimeric receptor complex and further induction of signal transduction. The activity of Jak kinases is induced by phosphorylation of tyrosine residues in the kinase activation loop (A-loop) through auto-or transphosphorylation by another Jak kinase. The Aloop in Jak kinases contains a conserved YY motif and the functional role of these tyrosines varies between different Jaks. Phosphorylation of the first tyrosine in the YY motif greatly increases the activity of Jak1 and Jak2, but has a less pronounced effect in Jak3 (22, 25, 26) .
Mutation of the second tyrosine in the YY motif increases the activity of Jak3, while similar mutations in Jak1 or Jak2 have no effect (22, 25, 26) . The double tyrosine motif is also a target for negative regulation of Jaks. SOCS-1 and SOCS-3 directly bind to the activation loop of Jak2 to downregulate kinase activity, and in the case of SOCS-1 this interaction has been shown to induce ubiquitination of Jak2 (27-29). Also, the protein tyrosine phosphatase PTP1B downregulates IFN-γ and IFN-α signalling by recognizing and specifically dephosphorylating the double tyrosine motifs of Jak2 and Tyk2 (30) . Jak3 and Jak1, on the other hand, are negatively regulated through the T cell PTPase, TCPTP (31).
Although catalytically inactive, the JH2 domain has been found to be a critical regulator of Jak kinases. We have previously found that JH2 is a negative regulatory domain in Jak2, and deletion of this domain leads to activation of Jak2 (23) . A mutation in the JH2 domain of Drosophila Jak kinase, Hop, has been found to up-regulate kinase activity and result in leukaemia in the fly, also supporting a role for JH2 in negative regulation of Jaks (32) . On the other hand, mutations in the Jak3 JH2 domain have been found to inactivate the 5 kinase, and result in abrogation of IL-2 signalling leading to SCID (33, 34) . Similarly, mutations in the JH2 domain of Tyk2 have been shown to interfere with Tyk2 activity, and deletion of JH2 resulted in inactivation of the kinase (35, 36) . Thus, the JH2 domain has been found to regulate Jak activity either positively or negatively, leaving the role of the JH2 domain in Jaks still unclear. Furthermore, it is currently not known, if the JH2 domain has a conserved function in regulating Jak activity or if the role of the JH2 domain is distinct in different Jaks.
In this study we have compared the JH2 mediated regulation of Jak2 and Jak3 to elucidate the function of the JH2 domain in cytokine signalling. Our results demonstrate that the JH2 domain is required to maintain low basal activity of both Jak2 and Jak3. 
DNA constructs
The amino acids encoded by the Jak2 and Jak3 constructs are shown in Figures 3A,
4A and 5A and the numbering refer to mouse Jak2 (GenBank accession L16956) and Jak3
(GenBank accession L32955) sequences. Expression vectors for Jak2, JH2∆-Jak2 and JH1-Jak2 have been described previously and they contain the hemagglutinin tag (HA) in their Cterminus (23) . The mouse Jak3 plasmid is described previously, except for a HA-tag, which was added to the C-terminus of Jak3 (40) . Jak2 and Jak3 constructs were prepared using PCR and cloned into the pCIneo expression vector (Promega, Madison, WI). New translation 7 initiation codons were introduced by PCR into HA-tagged Jak3 to create JH1-2-Jak3 and JH1-Jak3. JH2∆-Jak3 and Jak323 were constructed using recombinant PCR creating a deletion and a chimeric construct, respectively. Jak232 was constructed using recombinant PCR creating a chimeric construct with one amino acid change (P841S) in the linker between the kinase and pseudokinase domains. Prediction of the protein domains was done using the Smart program (41) . All PCR products were confirmed by sequencing (Applied Biosystems).
Expression vector for Stat5A and luciferase reporter construct containing the Stat5 binding site from the promoter of the Serine protease inhibitor gene (pSPI-luc2) were kind gifts from Dr. Tim Wood (42) . Luciferase reporter construct containing the Stat1 binding site from the promoter of the IRF-1 gene was a kind gift from Dr. Richard Pine (43) .
Immunoblotting, immunoprecipitation, kinase and luciferase assay
Cells were lysed in kinase lysis buffer (10 mM Tris-HCl, pH 7.5, 1 % Triton X-100, 20 % glycerol, 5 mM EDTA, 50 mM NaCl, 50 mM NaF, 1 mM Na 3 VO 4 ) supplemented with protease inhibitors, and the lysates were used for immunoprecipitation or directly for western blotting. The immunoprecipitation protocol has been described (44) . The immunoprecipitates were subjected to Western blotting or used for kinase assay. For kinase assay, the immunoprecipitates were washed four times with kinase lysis buffer and twice with kinase assay buffer (10 mM HEPES, pH 7.4, 50 mM NaCl, 5 mM MgCl 2 , 5 mM MnCl 2 , 50 mM NaF, 0.1 mM Na 3 VO 4 ). The immunoprecipitates were suspended in kinase assay buffer containing DTT (1mM). The following peptides (1 mg/ml) were used as substrates: Stat5 (AKAADGYVKPQIKQVV), Jak1YY (AIETDKEYYTVKDDRDS), Jak2YY
(VLPQDKEYYKVKEPGES) or Jak3YY (LLPLDKDYYVVREPGQK). 10 µCi [γ-33 P] ATP was added to the reactions followed by 10 min incubation at room temperature and boiling in reducing Laemmli sample buffer. The reactions were separated in 20% SDS-PAGE followed by quantification of radioactivity using PhosphorImager (Fuji). 
Results

Jak2 has low kinase activity when compared to Jak1 or Jak3
We have previously investigated the role of the different JH domains in regulation of Jak2 and found that the pseudokinase domain, JH2, negatively regulates the activity of Jak2 (23) . Since the pseudokinase domain is conserved within Jak family, we wanted to investigate the function of the pseudokinase domain also in other Jak kinases. In addition, we sought to determine if the pseudokinase domains regulate different Jak kinases similarly or if this domain mediates distinct functions in different Jak kinases.
We started the analysis by comparing the activities of Jak1, Jak2 and Jak3. HAtagged Jak1, Jak2 and Jak3 kinases were expressed in 293T cells and the Jak proteins were immunoprecipitated using anti-HA antibody. The immunoprecipitates were subjected to in vitro kinase assay using four different peptide substrates corresponding to the double tyrosine motifs in the kinase activation loop of Jak1, Jak2 and Jak3 and the tyrosine phosphorylation site in Stat5 (Y694) (22, 25, 26, 45) . The activity of Jak2 towards any of the substrate peptides was extremely low when compared to the activities of either Jak1 or Jak3 (Fig. 1A) , although Jak2 was expressed at much higher level than Jak1 or Jak3 ( Fig 1B) . The expression of Jak3 was repeatedly very low, and difficult to detect using the monoclonal anti-HA antibody, but could be detected using polyclonal Jak3 antiserum (not shown). Despite lower level of expression, tyrosine phosphorylation of Jak3 was very similar to that of Jak2, indicating that Jak3 was phosphorylated at higher level than Jak2 (Fig. 1B ). Also Jak1 had higher level of tyrosine phosphorylation than Jak2. Interestingly, Jak1 and Jak3 showed clear differences in phosphorylation of the substrate peptides. The Stat5 derived peptide was the best substrate for Jak1, while Jak3 showed preference for the A-loop derived peptides of Jak1, Jak2 and Jak3 kinases (Fig. 1A) .
The results from the kinase assay indicated that the activity of Jak2 was clearly lower than the activity of either Jak1 or Jak3. We considered two possible explanations for this 10 finding. The difference in kinase activity might be due to different activity of the tyrosine kinase domains. Alternatively, but not exclusively, the kinase domains might be differentially regulated by other domains, such as the pseudokinase domain, in full-length Jak kinases. We first analysed the activities of the isolated tyrosine kinase domains, and chose to compare the activities of Jak2 and Jak3, which showed the greatest difference in the kinase assay. A construct coding for the tyrosine kinase domain of Jak3, JH1-Jak3, and JH1-Jak2 (23), were expressed in 293T cells. The JH1 domains were immunoprecipitated using anti-HA antibody and subjected to in vitro kinase assay with Stat5 peptide as a substrate ( Fig. 2A ) or to immunoblotting with anti-HA or anti-phosphotyrosine antibodies (Fig. 2B ). Despite lower level of expression, JH1-Jak3 had both higher kinase activity and higher level of tyrosine phosphorylation than JH1-Jak2, indicating that the tyrosine kinase domain of Jak3 was more active than that of Jak2.
The JH2 domain negatively regulates Jak3
We previously found that deletion of JH2 resulted in activation of Jak2. To compare the pseudokinase domain mediated regulation of Jak2 and Jak3, we created deletion constructs including JH2∆-Jak3, a Jak3 protein lacking the pseudokinase domain, JH1-JH2-
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To analyse if the JH2 domain inhibited also downstream signalling by Jak3, we coexpressed the different Jak3 deletion mutants with Stat5A. The ability of the Jak3 kinases to mediate tyrosine phosphorylation of Stat5 was analysed after Stat5 immunoprecipitation by anti-phosphotyrosine immunoblotting (Fig. 3D) . When compared to Jak3, JH2∆-Jak3 as well as JH1-Jak3 induced increased tyrosine phosphorylation of Stat5 (Fig. 3D) . The JH1-JH2-Jak3, on the other hand, resulted in Stat5 phosphorylation comparable to Jak3 (Fig. 3D) .
Thus, the JH2 domain inhibited also the ability of Jak3 to activate Stat5.
We next analysed, if the increase in tyrosine phosphorylation of the Jak3 mutants lacking JH2 correlated with their in vitro kinase activity. Jak3 and the Jak3 deletion constructs, JH2∆-Jak3, JH1-Jak3 and JH1-2-Jak3, were expressed in COS cells, and the Jak3
immunoprecipitates were analysed in in vitro kinase assay using as a substrate a peptide containing the A-loop double tyrosine motif of Jak3 (Fig. 3E) . Immunoblotting with anti-Jak3 antibody confirmed equal protein levels of the different Jak3 kinases in immunoprecipitates and total cell lysates (not shown). Compared to untransfected control, Jak3 showed clear phosphorylation of the peptide substrate (Fig. 3E) . Slight increase in kinase activity was seen with the JH2∆-Jak3 when compared to Jak3 (Fig. 3E) . Also, the activity of JH1-Jak3 was increased over twofold when compared to Jak3. However, the activity of JH1-2-Jak3 was less than one third of the activity of JH1-Jak3 indicating that the presence of JH2 reduced the activity of JH1-Jak3 (Fig. 3E) . The lower activity of JH1-2-Jak3 compared to Jak3 is in line with the results showing that the N-terminal FERM-domain positively regulates Jak3 (24) . In summary, the results from Figure 3 indicated that Jak3 is negatively regulated by its pseudokinase domain.
The JH2 domains of Jak2 and Jak3 are interchangeable
The pseudokinase domain mediated negative regulation of Jak3 showed analogy to our previous results with Jak2. However, deletion of JH2 increased the kinase activity of Jak3 only slightly, while we previously found a robust increase in kinase activity of Jak2 upon deletion of the JH2 domain. Thus, we considered the possibility that the JH2 domain of Jak3 was not as efficient in inhibiting Jak activity as Jak2 JH2 and decided to investigate how similar the individual pseudokinase domains of Jak2 and Jak3 are functionally. We cloned chimeric constructs; one where the JH2 domain of Jak2 was replaced by that of Jak3 ( Fig.   4A ) and one where the JH2 domain of Jak3 was replaced by that of Jak2 (Fig. 5A ), generating the Jak232 and Jak323 constructs, respectively. These constructs left intact the entire tyrosine kinase domains and the adjacent linker regions between the kinase and pseudokinase domains.
To analyse if the pseudokinase domain of Jak3 was able to complement the pseudokinase domain of Jak2, the Jak232 chimeric construct was transiently expressed. As a control we expressed both Jak2 and JH2∆-Jak2, a Jak2 kinase lacking the pseudokinase domain ( Fig. 4A ) (23) . The Jak2 proteins were immunoprecipitated and analysed by antiphosphotyrosine immunoblotting. While JH2∆-Jak2 showed significantly increased tyrosine phosphorylation when compared to Jak2, tyrosine phosphorylation of Jak232 was equal to Jak2 (Fig. 4B) . We also analysed the signalling properties of the Jak232 chimera by coexpressing it with Stat5. Jak232 and Jak2 phosphorylated Stat5 at similar levels, while JH2∆-Jak2 induced significantly increased tyrosine phosphorylation of Stat5 (Fig. 4C) . Thus, the pseudokinase domain of Jak3 was able to restore wild type function in Jak2, suggesting that it was functionally similar to the pseudokinase domain of Jak2.
Similarly, the function of the Jak2 JH2 in the context of Jak3 was analysed by transiently expressing the Jak323 chimeric construct (Fig. 5A) . As a control we expressed either wild type Jak3 or JH2∆-Jak3. Tyrosine phosphorylation of Jak323 was found to be equal to Jak3, while JH2∆-Jak3 showed significantly increased tyrosine phosphorylation (Fig.   5B ). The ability of Jak323 to induce downstream signalling was analysed by co-expressing it with Stat5. The results show that Jak323 and Jak3 phosphorylated Stat5 at similar levels, while JH2∆-Jak3 induced increased Stat5 phosphorylation (Fig. 5C) . Thus, the pseudokinase domain of Jak2 was able to inhibit Jak3 function in the chimeric Jak323 kinase.
13
The JH2 domain is required for inhibition of the basal activity of Jak2 and Jak3
kinases and for cytokine-inducible signal transduction
We next wanted to analyse the function of the pseudokinase domain of Jak3 in cytokine receptor signalling, where activation of Jak3 is dependent on cytokine induced receptor dimerization. We chose to use the IL-2 receptor, where Jak3 is an essential kinase for downstream signalling. We created an IL-2-dependent receptor system in 293 cells, which lack endogenous Jak3, by expressing β and γ chains of the IL-2 receptor together with Stat5 and the different Jak3 kinase constructs. Activation of Stat5 was monitored by Stat5-dependent luciferase reporter. As shown in Fig.6A , IL-2 did not induce signalling in the absence of Jak3, confirming that also in the reconstituted system signalling through the IL-2 receptor was dependent on Jak3. Stimulation of Jak3 transfected cells with IL-2 resulted in significant increase in Stat5-dependent luciferase activity (Fig. 6A) . In contrast, transfection of JH2∆-Jak3 resulted in slightly increased Stat5 activation in the absence of IL-2, and notably, this activity did not increase following IL-2 treatment. Jak323 was able to induce Stat5 activation upon IL-2 stimulation, although not to the level of wild type Jak3. Thus, the results from the IL-2 receptor system also supported a role for JH2 in inhibition of the basal activity of Jak3. Furthermore, the JH2 domain was essential for IL-2 inducible activation of Stat5. This function was restored in the chimeric Jak3 construct containing the JH2 domain of Jak2, although not to the level of Jak3.
To test the function of the Jak3 pseudokinase domain in Jak2 in IFN-γ signalling, we transiently expressed Jak2, JH2∆-Jak2 or Jak232 together with a Stat1 dependent luciferase reporter construct in a Jak2 negative cell line, γ2A. We previously found that expression of JH2∆-Jak2 in γ2A cells results in cytokine-independent activation of Stat1 (23). Transfection of Jak2 had no effect on Stat1 activation, but stimulation of the Jak2 transfected cells with IFN-γ resulted in significant Stat1 activation ( the JH2 domain of Jak3 was able to restore wild type regulation of Jak2 in IFN-γ signalling, demonstrating functional similarity between the JH2 domains of Jak2 and Jak3. In summary, our results indicated that a functional pseudokinase domain is required for suppression of the basal activity of Jak2 and Jak3 kinases. Moreover, the pseudokinase domain is required to render Jaks competent to respond to cytokine stimulation with induction of Stat activation.
We next directly analysed the role of JH2 on cytokine-induced Jak activation. Jak2
and JH2∆-Jak2 were expressed in γ2A cells, and activation of the Jak2 kinases was analysed after IFN-γ stimulation by anti-phosphotyrosine immunoblotting (Fig.7) . Tyrosine phosphorylation of Jak2 was induced upon IFN-γ treatment, while JH2∆-Jak2 showed constitutive phosphorylation, which was unresponsive to IFN-γ (Fig.7, left panel) . When the tyrosine phosphorylation levels of Jak2 and JH2∆-Jak2 were normalised to the protein levels shown in anti-HA immunoblot (Fig.7, right panel) , tyrosine phosphorylation of JH2∆-Jak2 was found to be much higher than that of Jak2. Thus, the JH2 domain was required for inhibition of basal Jak2 activity and for IFN-γ induced activation of Jak2.
To elucidate the mechanism of JH2 mediated induction of Jak2 activity, we analysed if the JH2 domain was required for the reciprocal interaction and subsequent activation of Jak1 and Jak2 kinases. We coexpressed kinase inactive forms of Jak2 (KN-Jak2) and JH2∆-Jak2 (KN-JH2∆-Jak2) with wild type Jak1. The kinase inactive Jak2 proteins were immunoprecipitated, and their tyrosine phosphorylation was analysed. Jak1 was found to equally phosphorylate the KN-Jak2 and KN-JH2∆-Jak2 proteins (Fig.7B) . The tyrosine phosphorylation of the kinase-inactive Jak2 proteins was decreased with increasing Jak2 protein levels, most likely due to inhibition of Jak1 activity by kinase-inactive Jak2 proteins.
Thus, Jak1 phosphorylates both kinase negative Jak2 proteins, and the Jak1-Jak2 interaction does not require the JH2 domain. However, in Jak receptor-complexes ( 
Discussion
The Jak kinases form a distinct family of cytoplasmic tyrosine kinases characterized by the double kinase domain motif. Since cloning of the four known Jak kinases the function of the second, inactive kinase domain has been a question of interest. Recent reports have
shown that the JH2 domain is differentially involved in regulation of the various Jak kinases, raising the question if the JH2 domains regulate Jak kinases similarly or if the JH2 domains mediate distinct functions in different Jak kinases (23, 34, 36) . Likewise, the exact mechanisms of the JH2 mediated regulation have remained elusive. In this study, we found that the function of the JH2 domain is, to a high degree, conserved between Jak2 and Jak3. In addition, we show that the JH2 domain has a critical role in regulating cytokine responsiveness of cells and propose a novel function for the JH2 domain in Jak-receptor complexes.
Deletion of JH2 was found to increase tyrosine phosphorylation of Jak3 itself and result in constitutive activation of Stat5, thus identifying a negative regulatory role for the JH2 domain in Jak3. These findings are in line with our earlier results regarding regulation of Jak2 (23) , and indicate similar regulation of Jak2 and Jak3 by their JH2 domains. Also, a chimeric Jak2 kinase containing the JH2 domain of Jak3 behaved as wild type Jak2, indicating that the Jak3 JH2 domain was very similar in function to the JH2 domain of Jak2.
Notably, despite increased basal activity, the Jak2 and Jak3 JH2 deletion mutants were Our results show that although JH2 was essential for cytokine-inducible activation of signalling, this domain was not required for kinase activity of Jak3 or Jak2 as such, since Jak kinases lacking JH2 retained catalytic activity. Previously, either deletion or point mutations in the JH2 domains of Jak3 and Tyk2 have been found to prevent cytokine signalling, possibly due to lack of kinase activity of these mutant kinases (34) (35) (36) . These seemingly contradictory results may be explained in regard to the central function of the JH2 domain in Jak kinases. It is evident that the JH2 domain is tightly connected to the function of the following tyrosine kinase domain. Thus, various mutations and small differences in the deleted JH2 regions appear to produce Jak mutants with different activity, and in certain Jaks, the JH2 domain may not be deleted without disturbing the JH1 function. Here, using murine Jak2 and Jak3 we have been able to delete JH2, while retaining catalytic activity of these kinases. Thus, our results indicate a novel function for the JH2 domain, which cannot be explained by the lack of kinase activity of the deletion mutants. Interestingly, despite similar inhibitory JH2 domains, the basal activity of Jak2 was much lower than that of Jak3, indicating that the two kinases are differentially regulated. Our results indicate that the JH1 domains may have inherently different activities, which is in line with the different role of Aloop tyrosines in different Jaks. These results also support the conclusion that the deletion of JH2 may have distinct effects in different Jaks due to differential activation requirements of the JH1 domains.
Previously, the JH2 domain has been suggested to inhibit the kinase domain through intramolecular interaction by preventing the access of substrates and ATP to the catalytic cleft in the absence of cytokine stimulation (23, 34) . Cytokine stimulation leading to juxtaposition of Jaks would relieve this inhibition, and our results indicate that in cytokine receptor signalling the subsequent activation of Jaks as well as Stats requires the JH2 domain. Our
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results showing that i) the Jak JH2 deletion mutants were catalytically active, ii) were able to activate Stat5 and interact with other Jaks, and iii) the results from other groups that JH2 is not required for coupling Jaks to cytokine receptors, collectively indicate that Jaks are able to interact with all components of the signalling pathway in the absence of JH2, but the JH2 domain is required to connect cytokine receptor activation to Jak activation and induction of signalling. Thus, the functions of JH2 are important in the context of the Jak-receptor complex. Induction of negative feedback regulation by the constitutively active JH2 deletion mutants, for example through expression of SOCS proteins, is one plausible explanation for the lack of cytokine responsiveness. However, the relatively low activity of JH2∆-Jak3 in the IL-2 receptor model is unlikely to result in prevention of further signalling by IL-2.
Alternatively, the JH2 domain may be required for the JH1 domain to acquire its fully active conformation. However, the Jak2 JH1 domain is extremely active compared to full length Jak2, making this explanation less likely.
A more likely explanation for the JH2 requirement for cytokine-inducible signalling would be that the JH2 domain has an active structural role in Jak-receptor signalling complexes by contributing to the formation of the active configuration of the receptor complex following cytokine binding. In the resting state JH2 mediates inhibitory interaction with JH1, but ligand-induced conformational changes in the receptor may trigger interactions between JH2 and other protein domains in the receptor complex. Interestingly, Jaks have been found to be essential structural components of cytokine receptors. Specifically, Jaks have been found to interact with the receptor in multiple ways, one interaction being required for cell surface expression of certain cytokine receptors and for initial binding of Jak2 to its receptor, and the other one required for Jak activation (19, 20) . Recently, receptor epitopes required for efficient activation of Jaks were identified that are not involved in the initial binding of Jaks to the receptor (19, 47, 48) . These studies indicated that the cytoplasmic domain of the receptor must adopt a highly ordered structure to allow Jak activation (47, 49) .
Interestingly, activation of Jak2 by EPO requires a membrane proximal hydrophobic motif in the EPO receptor, which is suggested to interact with the C-terminal JH1-2 region of Jak2 (19, 47) . This result, and our data on the role of JH2 in induction of Jak activity following cytokine treatment, suggest that cytokine-induced change in the configuration of the receptor complex enables JH2 mediated interactions, which are required for progression of signal transduction.
Although the JH2 domains mediated similar regulatory functions in Jak2 and Jak3, the JH2 domains functioned slightly differentially in signalling through the IFN-γ and IL-2 receptors. Deletion of JH2 resulted in constitutive Stat activation, but this activation was lower in IL-2 signalling than in IFN-γ signalling. Similarly, the Jak2 and Jak3 chimeras restored inducible Stat activation by IFN-γ and IL-2, respectively, but while the Jak232 chimera behaved as wild type Jak2 in IFN-γ signalling, the Jak323 chimera was not as potent in inducing Stat activation by IL-2 as wild type Jak3. On the other hand, in a receptor independent system, the Jak3 chimera behaved as wild type Jak3. These results suggested that the JH2 domain was more critical for signalling through the IL-2 receptor than through the IFN-γ receptor, and that the JH2 domain of Jak3 may have a very specific role in the IL-2 receptor, which cannot be totally complemented by the JH2 domain of Jak2.
In line with our results, mutations in JH2 causing SCID, resulted in constitutive tyrosine phosphorylation of Jak3, but failure of Jak3 to mediate significant downstream signalling from the IL-2 receptor (33, 34) . The SCID JH2 domains were found to be more potent inhibitors of the Jak3 JH1 domain than the wild type JH2 domain, thus explaining for the abrogation of signaling by the SCID mutations. Since our constructs do not contain JH2, the lack of inducible signaling in our experiments is not due to increased inhibition by JH2.
Thus, our results on the critical role of the JH2 domain in regulating basal as well as IL-2-inducible Jak3 activation may give an additional explanation for the SCID phenotype of JH2 mutations in Jak3, which may contribute to disease pathogenesis in the SCID patients by enforcing the effects of the SCID JH2 mutations. The Jak3 mutants causing SCID were capable of inducing IL-4 signalling, although at a reduced level when compared to wild type Jak3 (33) . Thus the role of Jak3 JH2 is particularly critical in the IL-2 receptor and less in IL-4 signalling, where Stat activation can be induced also in the absence of Jak3 (50). Our results suggest that JH2 interacts with other protein domains in receptor complexes to regulate cytokine-responsiveness, and it is possible that these interactions are receptor specific, thereby explaining for the distinct functions of JH2 domains in different cytokine receptors.
The result that Jak3 showed preference for Jak autophosphorylation peptides, while the Stat5 derived peptide was a better substrate for Jak1, support a model for IL-2 signalling, where Jak3 activates Jak1, which then phosphorylates Stat5. However, Jak3 lacking functional JH2 is expected to be defective in activation of Jak1, which might perturb downstream signalling, thus explaining for the critical role of JH2 in IL-2 signalling. In line with this notion, Stat5 has been previously found to be a better substrate for Jak1 than for Jak3 (22) . Furthermore, deletion of JH2 abolished IFN-γ -inducible Jak2 activation, indicating that the reciprocal activation of Jaks was prevented upon JH2 deletion. In IFN-γ signalling, Jak2 may be the Stat1 activating kinase, whereas Jak1 would be needed for activation of Jak2, and this activation step could be circumvented by activation of Jak2 through JH2 deletion.
This concept is supported by our results indicating that Stat1 can be activated by JH2∆-Jak2 in the absence of Jak1, while wild type Jak2 requires Jak1 in IFN-γ signalling (P. Saharinen and O. Silvennoinen, unpublished data).
In conclusion, our results show that the JH2 domain has a conserved function in Jak2
and Jak3 by regulating both basal as well as inducible Jak activity in Jak-receptor complexes.
The JH2 domain may be viewed as an inducible switch in Jak kinases enabling initiation of signal transduction in response to cytokine stimulation. This regulation most likely requires interaction of the JH2 domain with other proteins in Jak-receptor complexes. These interactions remain to be identified, but the conserved, α-helical membrane proximal domain in ligand-bound cytokine receptors is one potential interaction site (47) . Prevention of the JH2 mediated interaction essential for cytokine signalling may give an alternative for development of a more specific inhibitor for cytokine-induced Jak signalling. A. The Jak2 constructs coding for the mouse Jak2 kinase (Jak2), Jak2 where the JH2 domain has been deleted (JH2∆-Jak2) and Jak232 chimera containing the JH2 domain of Jak3 A. The Jak3 constructs coding for the mouse Jak3 kinase (Jak3), Jak3 where the JH2 domain has been deleted (JH2∆-Jak3) and Jak323 chimera containing the JH2 domain of Jak2 (Jak323) are shown schematically and amino acids are numbered according to the mouse Jak3 and Jak2 sequences. The cDNAs carry a HA-tag in the C-terminus. B. Jak3, JH2∆-Jak3 and 
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